BLFS

BioLife Solutions Inc

Add to Watchlist

Advanced Chart

24.600

+0.26(1.068%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.610

Open

24.285

VWAP

24.35

Vol

15.62K

Mkt Cap

1.17B

Low

24.285

Amount

380.42K

EV/EBITDA(TTM)

256.04

Total Shares

46.07M

1.09B

EV/OCF(TTM)

70.41

P/S(TTM)

12.22

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

25.69M

-15.96%

26.61M

+17.16%

27.03M

+12.91%

Estimates Revision

The market is revising Upward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by 1.27% over the past three months. During the same period, the stock price has changed by 7.24%.

Revenue Estimates for FY2025

Revise Upward

+1.27%

In Past 3 Month

Stock Price

Go Up

+7.24%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 31.00 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.600

Low

30.00

Averages

31.00

High

34.00

Current: 24.600

Low

30.00

Averages

31.00

High

34.00

H.C. Wainwright

Buy

maintain

$30 -> $32

2025-08-08

Reason

H.C. Wainwright

Price Target

$30 -> $32

2025-08-08

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.

Stephens

Overweight

initiated

$30

2025-07-21

Reason

Stephens

Price Target

$30

2025-07-21

initiated

Overweight

Reason

Stephens resumed coverage of BioLife Solutions with an Overweight rating and $30 price target and named the stock as the analyst's "Best Idea." BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment "represents a crown jewel asset" as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$27 → $30

2025-03-06

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$27 → $30

2025-03-06

Maintains

Strong Buy

Reason

Northland Capital Markets

Carl Byrnes

Buy

Maintains

$28 → $31

2025-01-08

Reason

Northland Capital Markets

Carl Byrnes

Price Target

$28 → $31

2025-01-08

Maintains

Buy

Reason

Benchmark

Robert Wasserman

Strong Buy

Reiterates

$30

2024-12-19

Reason

Benchmark

Robert Wasserman

Price Target

$30

2024-12-19

Reiterates

Strong Buy

Reason

Keybanc

Paul Knight

Buy

Maintains

$30 → $33

2024-12-13

Reason

Keybanc

Paul Knight

Price Target

$30 → $33

2024-12-13

Maintains

Buy

Reason

KeyBanc raised the firm's price target on BioLife Solutions to $33 from $30 and keeps an Overweight rating on the shares. BioLife, under its new CEO, has completed a quick succession of three asset sales, and the firm's proforma models show a high-growth and high-margin business with its dominance of freeze media for the cell, gene, and CAR-T markets, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLife Solutions Inc (BLFS.O) is -3245.33, compared to its 5-year average forward P/E of -1566.32. For a more detailed relative valuation and DCF analysis to assess BioLife Solutions Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1566.32

Current PE

-3245.33

Overvalued PE

4237.46

Undervalued PE

-7370.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

91.77

Current EV/EBITDA

40.54

Overvalued EV/EBITDA

203.94

Undervalued EV/EBITDA

-20.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

8.88

Current PS

10.78

Overvalued PS

12.69

Undervalued PS

5.07